Drug Trial Radar · NCT07351968
A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Mar 10, 2026
Primary completion
Jul 17, 2026
Study completion Jul 17, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.
Conditions
- Moderate Pain in Knee Osteoarthritis
- Severe Pain in Knee Osteoarthritis
Interventions
HRS-2129 TabletDrug
HRS-2129 tablet.
Celecoxib capsuleDrug
Celecoxib capsule.
Celecoxib Capsule PlaceboDrug
Celecoxib capsule placebo.
HRS-2129 Tablet PlaceboDrug
HRS-2129 tablet placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.Time frame: At week 4.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Drum Tower Hospital affiliated to Nanjing University School of Medicine
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.